PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. They do not have biosimilar or generic competition available in the market.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarivate

AUGUST 7, 2024

The three largest pharmacy benefit managers (PBMs) in the United States—Express Scripts, OptumRx and CVS Caremark—control more than 80% of the market share (per Clarivate data, as of January 2024). This market dominance, coupled with other concerns, particularly around pricing opacity, has made PBMs a target of regulators and politicians.

Retail 59

Retail Marketing Competition Biopharma 59

Legacy MEDSearch

MARCH 7, 2024

Dexcom disclosed its plans to make Stelo available for purchase online without the need for a prescription, starting in summer 2024. The company aims to offer the device at a competitive price point, but further pricing details will be shared closer to the product’s release date.

Food and Drug Administration 52

Food and Drug Administration FDA Food Management 52

European Pharmaceutical Review

JULY 4, 2024

1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. The MA pathway is applicable for herbal medicines designed to treat more serious health conditions and require a medical prescription or the supervision of a medical practitioner. 2012/1916).

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

pharmaphorum

JANUARY 24, 2023

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Medicine 91

Medicine Healthcare Healthcare Pharma 91

PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. In 2024, ARPA removes the 100% AMP cap.

Management 105

Management Manufacturing Sales Competition 105

PM360

APRIL 7, 2023

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Expect the nine competitors to explore Kotler’s 4Ps of Marketing to gain share in this lucrative and competitive marketplace.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

PM360

SEPTEMBER 28, 2022

In April 2022, we released an article describing proposed policies from the federal government that could impact prescription drug pricing. How drug manufacturers should prepare for 2024: Have a strategy for request-for-proposal (RFP) season: RFPs for plan year 2024 will come out in late 2022 and run into early 2023.

Government 97

Government Manufacturing Prescription Competition 97

PM360

DECEMBER 20, 2023

A significant battle for the hearts and minds of healthcare professionals (HCPs) will play out in social media during 2024. Fifty percent of responders said they changed prescriptions because of social media information.

Media 122

Media Physicians Pharma reps Pharma Rep 122

Pharmaceutical Technology

JANUARY 6, 2023

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

Pharmaceutical 97

Pharmaceutical Doctors Healthcare Provider Prescription 97

Pharmaceutical Technology

DECEMBER 4, 2022

Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Samsung Bioepis and Organon previously stated that Hadlima's interchangeability data should be ready in 2024. Biosimilar uptake could be more gradual.

Marketing 104

Marketing Physicians Competition Patients 104

Clarivate

AUGUST 20, 2024

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

OCTOBER 17, 2024

Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. Such a change would sharply increase the number of people covered under this program.

Healthcare 52

Healthcare Healthcare Government Insurance 52